EVOLUS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.51 USD | -3.32% |
|
-8.39% | +19.18% |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Evolus First Qua...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Sector
Pharmaceuticals
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.94
USD
Average target price
22.29
USD
Spread / Average Target
+72.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.18% | 810M | |
| +39.63% | 723B | |
| +34.28% | 595B | |
| -4.15% | 369B | |
| +20.29% | 332B | |
| +2.83% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| +0.07% | 168B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Transcript : Evolus, Inc., Q1 2023 Earnings Call, May 09, 2023
